The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, ...

A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, finding the companies sometimes increased prices of these drugs by 1,000 ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

A yearslong Federal Trade Commission probe, resulting in a report released in July, reported that of the six pharmacy benefit ...

When talking about the influence of pharmacy benefit managers, U.S. Sen. James Lankford exhibits a mastery of how companies like CVS Health control where patients get their medicine, what ...

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen.

WASHINGTON, Jan 14 (Reuters) - The nation's three largest pharmacy ... FTC spokesperson told reporters in a press briefing, adding that the figure was "probably an underestimate." Pharmacy benefit ...

The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers could be inflating drug costs in the U.S., in the latest and likely ...